Cerevel Therapeutics has begun a study of an experimental drug called CVL-751 as a possible treatment for people with Parkinson’s disease.
About this study
The main purpose of this study is to learn how safe the study is and how well it works. This is a randomised, double-blinded trial for people in the early stages of Parkinson's disease.
Who can take part
Participants must meet the following criteria:
- People aged 40 to 80 years, inclusive
- People who are sexually active must agree to use acceptable (at minimum) or highly effective birth control
- Individuals must be capable of giving signed informed consent
- Individuals who are able, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures
- Visits every three weeks for the duration of the study
- Blood tests
- Complete questionnaires
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.
The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.
The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.